Phase 1/2 RCT of 120 patients with metastatic pancreatic cancer after gemcitabine: second-line nal-IRI plus S-1 did not improve median PFS vs nal-IRI plus 5-FU/LV (2.2 vs 3.3 months; HR 1.27, p=0.26); median OS was 6.0 vs 9.1 months (p=0.054).
RCTn = 120
Gehrels et al. Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial